The treatment landscape for plaque psoriasis is entering a new era—and DS Research is proud to have played a role in making it possible.
Recently, Johnson & Johnson announced the FDA approval of ICOTYDE™ (icotrokinra), a first-in-class targeted oral peptide for the treatment of moderate-to-severe plaque psoriasis. You can read the full announcement here: FDA approval press release.
A Breakthrough for Patients
Psoriasis affects more than 8 million people in the United States alone, often impacting both physical comfort and quality of life.
ICOTYDE represents a significant advancement because it introduces a once-daily oral option that targets the IL-23 receptor—an important driver of inflammation in plaque psoriasis.
Unlike many existing therapies that rely on injections or infusions, this novel oral peptide offers a new level of convenience while delivering strong clinical outcomes demonstrated in multiple Phase 3 trials.
The Role of Clinical Research
Behind every FDA approval is a rigorous clinical development program. ICOTYDE was evaluated through an extensive series of global Phase 3 studies—including ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE—designed to assess safety, efficacy, and real-world applicability across diverse patient populations.
These trials not only measured skin clearance outcomes but also examined effectiveness in challenging areas such as the scalp, hands, feet, and other high-impact regions.
DS Research’s Contribution
DS Research is proud to have participated as a clinical trial site in the development of icotrokinra.
Our involvement reflects our ongoing commitment to:
- Advancing innovative therapies
- Supporting sponsors in complex clinical programs
- Delivering high-quality data that helps bring new treatments to patients faster
By working alongside leading pharmaceutical partners and dedicated study participants, we help translate scientific discovery into meaningful clinical outcomes.
Why This Matters
The approval of ICOTYDE signals a broader shift in how plaque psoriasis may be treated moving forward. With a targeted mechanism and oral administration, this therapy has the potential to reshape first-line systemic treatment approaches and expand options for patients and providers alike.
For DS Research, participation in trials like these underscores the importance of experienced clinical sites in accelerating medical innovation.
Looking Ahead
As new therapies continue to emerge, DS Research remains committed to supporting cutting-edge clinical development across dermatology and beyond. We are honored to contribute to studies that make a tangible difference in patients’ lives—and we look forward to future collaborations that push the boundaries of what’s possible in medicine.